The #1 Source for Information on Lobular Breast Cancer
What is Lobular Breast Cancer?
Lobular breast cancer, also called invasive lobular carcinoma (ILC), is the 2nd most common type of breast cancer, accounting for about 15% of all breast cancer diagnoses with over 48,000 cases diagnosed each year. It’s time to advance research to better understand ILC and its differences, and refine treatment for patients.
Hear from LBCA Scientific Advisory Board and other ILC experts
Watch the most recent webinars and interviews with SAB members, researchers, patient advocates, and more.
The Latest News
LBCA Lobular Breast Cancer Cross-Country Awareness Tour Sept. 26th – Oct. 15th, 2026
It’s Time to Talk About Lobular Breast Cancer! For LBCA’s annual campaign to raise awareness of Lobular Breast Cancer during October, Breast Cancer Awareness Month,
Research News
LBCA Research Grantee Interview: Exploring What Drives ILC Metastasis
LBCA recently spoke with Dr. Christina Curtis of Stanford University and ILC research advocate Deborah Romer about Dr. Curtis’s research project, Microenvironmental Determinants of Metastasis
Education & Advocacy
New ILC Focused Initiative at University of Colorado Anschutz Cancer Center
Researchers at the University of Colorado Anschutz Cancer Center have launched the Lobular Breast Cancer Initiative (LBCI), a new interdisciplinary program dedicated to advancing research
My ILC Story
My ILC Story: Meet Betsy and Hear Her Lobular Breast Cancer Story
My name is Betsy. My husband was in the Navy for 30 years, so my cancer experience spans three states. In 2013, my doctor in
ILC Clinical Trials
Patients with invasive lobular carcinoma (ILC) can advance understanding of the disease by joining clinical trials. Few trials focus solely on ILC due to its lower incidence (10-15% of all breast cancers), but participation is crucial. Increased research could help improve detection, treatment, prevention of metastasis, and ultimately, develop a cure.